{"id":3355,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"1995-08-09","marketCap":2.8994998931884766,"name":"Windtree Therapeutics Inc","phone":"12154889300","outstanding":9.180000305175781,"symbol":"WINT","website":"https://windtreetx.com/","industry":"Biotechnology"},"price":5.505,"year":2024,"month":4,"day":24,"weekday":"Wednesday","title":"Analysis of Windtree Therapeutics Inc's Management Team","date":"2024-04-24","url":"/posts/2024/04/24/WINT","content":[{"section":"Key Executives","text":"1. Craig Fraser - President and CEO: Craig Fraser leads Windtree Therapeutics Inc as the President and CEO. With over 20 years of experience in the pharmaceutical industry, Fraser brings strong leadership skills and a deep understanding of the sector. He played a pivotal role in the acquisition of Istari Oncology, which expanded the company's product portfolio and pipeline. Fraser's strategic vision drives the company's growth and innovation initiatives."},{"section":"Strategic Direction","text":"2. Brian Cali - Chief Financial Officer: Brian Cali serves as the CFO of Windtree Therapeutics Inc. His financial expertise and strong analytical skills contribute to the company's strategic decision-making process. Cali plays a vital role in evaluating potential partnerships and acquisitions, ensuring financial feasibility and long-term profitability."},{"section":"Performance","text":"3. John Holloway - Chief Medical Officer: John Holloway is the Chief Medical Officer at Windtree Therapeutics Inc. He brings extensive experience in clinical development and regulatory affairs. Holloway's expertise ensures the successful execution of clinical trials and adherence to regulatory guidelines, ultimately impacting the company's performance and market approval of its products."},{"section":"Risk Management","text":"4. Thomas Schreck - Chief Legal Officer: Thomas Schreck holds the position of Chief Legal Officer at Windtree Therapeutics Inc. His strong background in legal and compliance matters enables the company to effectively navigate complex regulatory frameworks and mitigate legal risks. Schreck's contributions to risk management safeguard the company's reputation and minimize potential legal challenges."},{"section":"Innovation and Research","text":"5. Erik Romslo - Chief Technology Officer: Erik Romslo serves as the Chief Technology Officer at Windtree Therapeutics Inc. With a focus on innovation and research, Romslo oversees the development of cutting-edge technologies and scientific advancements. His leadership in technological advancements enhances the company's competitiveness and positions it as a leader in the pharmaceutical industry."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1713776880,"headline":"Lexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics among healthcare movers","id":127140312,"image":"","symbol":"WINT","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3455546724"},{"category":"company","date":1713509400,"headline":"Windtree Therapeutics Inc trading halted, news pending","id":127119848,"image":"","symbol":"WINT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3452799746"},{"category":"company","date":1713441600,"headline":"Windtree Therapeutics Announces Reverse Stock Split","id":127075892,"image":"https://media.zenfs.com/en/globenewswire.com/5cb152ffc3562c654666ff8709891a52","symbol":"WINT","publisher":"Yahoo","summary":"WARRINGTON, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ: WINT) (“Windtree” or the “Company”), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today announced that the Company’s Board of Directors has approved a 1-for-18 reverse stock split of its issued and outstanding common stock, par value of $0.001 per share (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 11:59 p.m. E","url":"https://finance.yahoo.com/news/windtree-therapeutics-announces-reverse-stock-120000271.html"},{"category":"company","date":1713436740,"headline":"Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session","id":127077800,"image":"","symbol":"WINT","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3450361930"},{"category":"company","date":1713424020,"headline":"Windtree Therapeutics approves reverse stock split","id":127091024,"image":"","symbol":"WINT","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3450092417"},{"category":"company","date":1713424020,"headline":"Windtree Therapeutics announces 1-for-18 reverse stock split","id":127091023,"image":"","symbol":"WINT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3450092811"},{"category":"company","date":1713358680,"headline":"Windtree Therapeutics GAAP EPS of -$0.95","id":127067992,"image":"","symbol":"WINT","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3448750984"},{"category":"company","date":1713357360,"headline":"Windtree Therapeutics GAAP EPS of $1.04, revenue of $58.72M","id":127067993,"image":"","symbol":"WINT","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3448721707"},{"category":"company","date":1713355200,"headline":"Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates","id":127053370,"image":"https://media.zenfs.com/en/globenewswire.com/5cb152ffc3562c654666ff8709891a52","symbol":"WINT","publisher":"Yahoo","summary":"WARRINGTON, Pa., April 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided key business updates. “The end of 2023 and the past few months have been very productive at Windtree as we advanced clinical programs, executed a licen","url":"https://finance.yahoo.com/news/windtree-therapeutics-reports-fourth-quarter-120000964.html"},{"category":"company","date":1713337380,"headline":"Windtree Therapeutics reports Q4 EPS (95c) vs ($13.01) last year","id":127067996,"image":"","symbol":"WINT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3448300009"},{"category":"company","date":1713333240,"headline":"WINT Stock Earnings: Windtree Therapeutics Beats EPS for Q4 2023","id":127067997,"image":"","symbol":"WINT","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3448229096"}]}